HRP20210502T1 - Triterpenoidi modificirani na c-3 i c-17 kao inhibitori hiv-1 - Google Patents

Triterpenoidi modificirani na c-3 i c-17 kao inhibitori hiv-1 Download PDF

Info

Publication number
HRP20210502T1
HRP20210502T1 HRP20210502TT HRP20210502T HRP20210502T1 HR P20210502 T1 HRP20210502 T1 HR P20210502T1 HR P20210502T T HRP20210502T T HR P20210502TT HR P20210502 T HRP20210502 T HR P20210502T HR P20210502 T1 HRP20210502 T1 HR P20210502T1
Authority
HR
Croatia
Prior art keywords
image
alkyl
group
substituted
heteroaryl
Prior art date
Application number
HRP20210502TT
Other languages
English (en)
Inventor
Jie Chen
Yan Chen
Ira B. Dicker
Richard A. Hartz
Nicholas A Meanwell
Alicia Regueiro-Ren
Sing-Yuen Sit
Ny Sin
Jacob Swidorski
Brian Lee Venables
Original Assignee
VIIV Healthcare UK (No.5) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by VIIV Healthcare UK (No.5) Limited filed Critical VIIV Healthcare UK (No.5) Limited
Publication of HRP20210502T1 publication Critical patent/HRP20210502T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C12N9/506—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/52—Ortho- or ortho- and peri-condensed systems containing five condensed rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Claims (17)

1. Spoj Formule I, uključujući njegove farmaceutski prihvatljive soli: [image] , naznačen time što: R1 je izopropenil ili izopropil; A je -C1-6 alkil-OR0; gdje je R0 heteroaril-Q0; Q0 se bira iz skupine koju čine -H, -CN, -C1-6 alkil, -COOH, -Ph, -OC1-6 alkil, -halogen, -CF3, Y se bira iz skupine koju čine -COOR2, -C(O)NR2SO2R3, -C(O)NHSO2NR2R2, -SO2NR2C(O)R2, -tetrazol, te -CONHOH, gdje n = 1-6; R2 je -H, -C1-6 alkil, -C1-6 alkil supstituiran alkilom ili -C1-6 alkil supstituiran arilom; W je odsutan, ili je -CH2- ili -CO-; R3 je -H, -C1-6 alkil ili -C1-6 alkil supstituiran alkilom; R4 se bira iz skupine koju čine -H, -C1-6 alkil, -C1-6 alkil-C3-6 cikloalkil, -C1-6 alkil supstituiran s -C1-6, -C1-6 alkil-Q1, -C1-6 alkil-C3-6 cikloalkil-Q1, aril, heteroaril, supstituirani heteroaril, -COR6, -SO2R7, -SO2NR2R2, te [image] , [image] , gdje se G bira iz skupine koju čine -O-, -SO2- i -NR12-; gdje se Q1 bira iz skupine koju čine -C1-6 alkil, -C1-6 fluoralkil, heteroaril, supstituirani heteroaril, halogen, -CF3, -OR2, -COOR2, -NR8R9, -CONR8R9 i -SO2R7; R5 se bira iz skupine koju čine -H, -C1-6 alkil, -C3-6 cikloalkil, -alkil supstituiran s C1-6 alkilom, -C1-6 alkil-NR8R9, -COR3, -SO2R7 i -SO2NR2R2; uz uvjet da R4 ili R5 nije -COR6 kada je W -CO-; uz dodatni uvjet da se samo jedan od R4 ili R5 bira iz skupine koju čine -COR6, -COCOR6, -SO2R7 i -SO2NR2R2; R6 se bira iz skupine koju čine -H, -C1-6 alkil, -alkil supstituiran s C1-6 alkilom, -C3-6 cikloalkil, -C3-6 supstituirani-cikloalkil-Q2, -C1-6 alkil-Q2, -alkil supstituiran s C1-6 alkilom-Q2, -C3-6 cikloalkil-Q2, aril-Q2, -NR13R14, te -OR15; gdje se Q2 bira iz skupine koju čine aril, heteroaril, supstituirani heteroaril, -OR2, -COOR2, -NR8R9, SO2R7, -CONHSO2R3, te -CONHSO2NR2R2; R7 se bira iz skupine koju čine -H, -C1-6 alkil, -alkil supstituiran s C1-6, -C3-6 cikloalkil, -CF3, aril, te heteroaril; R8 i R9 se neovisno bira iz skupine koju čine -H, -C1-6 alkil, -alkil supstituiran s C1-6, aril, heteroaril, supstituirani aril, supstituirani heteroaril, -C1-6 alkil-Q2, te -COOR3, ili se R8 i R9 uzima zajedno sa susjednim N kako bi tvorili prsten kojeg se bira iz skupine koju čine: [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] i [image] ; M se bira iz skupine koju čine -R15, -SO2R2, -SO2NR2R2, -OH i -NR2R12; V se bira iz skupine koju čine -CR10R11-, -SO2-, -O- i -NR12-; uz uvjet da samo jedan od R8 ili R9 može biti -COOR3; R10 i R11 se neovisno bira iz skupine koju čine -H, -C1-6 alkil, -alkil supstituiran s C1-6 i -C3-6 cikloalkil; R12 se bira iz skupine koju čine -H, -C1-6 alkil, -C1-6 alkil supstituiran alkilom, -CONR2R2, -SO2R3, te -SO2NR2R2; R13 i R14 se neovisno bira iz skupine koju čine -H, -C1-6 alkil, -C3-6 cikloalkil, -alkil supstituiran s C1-6, -C1-6 alkil-Q3, -C1-6 alkil-C3-6 cikloalkil-Q3, te alkil supstituiran s C1-6-Q3; Q3 se bira iz skupine koju čine heteroaril, supstituirani heteroaril, -NR2R12, -CONR2R2, -COOR2, -OR2, te -SO2R3; R15 se bira iz skupine koju čine -C1-6 alkil, -C3-6 cikloalkil, -alkil supstituiran s C1-6, -C1-6 alkil-Q3, -C1-6 alkil-C3-6 cikloalkil-Q3 i -alkil supstituiran s C1-6-Q3; R16 se bira iz skupine koju čine -H, -C1-6 alkil, -NR2R2, te -COOR2; uz uvjet da kada je V -NR12-; R16 nije -NR2R2; i R17 se bira iz skupine koju čine -H, -C1-6 alkil, -COOR3, te aril.
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time što se u skupini R0 heteroarilni ostatak bira iz skupine koju čine: [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , te [image] .
3. Spoj u skladu s patentnim zahtjevom 2, naznačen time što je R1 izopropenil.
4. Spoj u skladu s patentnim zahtjevom 3, naznačen time što je Y -COOR2.
5. Spoj u skladu s patentnim zahtjevom 4, naznačen time što je R2 -H.
6. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je R4 -C1-6 alkil-Q1.
7. Spoj u skladu s patentnim zahtjevom 6, naznačen time što je Q1 -NR8R9.
8. Spoj u skladu s patentnim zahtjevom 7, naznačen time što kada se R8 i R9 uzima zajedno sa susjednim -N kako bi tvorili prsten, prsten se bira iz skupine koju čine: [image] i [image] .
9. Spoj u skladu s patentnim zahtjevom 8, naznačen time što se svakog od R7 i R16 bira iz skupine koju čine -H i -C1-6 alkil.
10. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je Q0 -CN.
11. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je R1 izopropenil, u skupini R0 "heteroarilni" ostatak se bira iz skupine koju čine: [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , te [image] ; Y je -COOH, R4 je -C1-6 alkil-Q1, Q1 je -NR8R9, a R8 i R9 se uzima zajedno sa susjednim -N kako bi tvorili prsten kojeg se bira iz skupine koju čine: [image] i [image] .
12. Spoj u skladu s patentnim zahtjevom 1, uključujući njegove farmaceutski prihvatljive soli, naznačen time što ga se bira iz skupine koju čine: [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] i [image] .
13. Spoj u skladu s patentnim zahtjevom 1, uključujući njegove farmaceutski prihvatljive soli, naznačen time što ga se bira iz skupine koju čine: [image] , [image] , [image] , te [image] .
14. Spoj, uključujući njegove farmaceutski prihvatljive soli u skladu s patentnim zahtjevom 13, naznačen time što je: [image] .
15. Pripravak, naznačen time što sadrži količinu koja ublažava HIV jednog ili više spojeva u skladu s patentnim zahtjevom 1-14, zajedno s jednim ili više farmaceutski prihvatljivih nosača, pomoćnih sredstava i/ili razrjeđivača.
16. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s patentnim zahtjevima 1-14, naznačen time što je namijenjen upotrebi u terapiji.
17. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s patentnim zahtjevima 1-14, naznačen time što je namijenjen upotrebi u liječenju sisavca zaraženog virusom HIV.
HRP20210502TT 2016-02-04 2021-03-29 Triterpenoidi modificirani na c-3 i c-17 kao inhibitori hiv-1 HRP20210502T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662291298P 2016-02-04 2016-02-04
PCT/IB2017/050568 WO2017134596A1 (en) 2016-02-04 2017-02-02 C-3 and c-17 modified triterpenoids as hiv-1 inhibitors
EP17704093.8A EP3411381B1 (en) 2016-02-04 2017-02-02 C-3 and c-17 modified triterpenoids as hiv-1 inhibitors

Publications (1)

Publication Number Publication Date
HRP20210502T1 true HRP20210502T1 (hr) 2021-05-14

Family

ID=57995251

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20210502TT HRP20210502T1 (hr) 2016-02-04 2021-03-29 Triterpenoidi modificirani na c-3 i c-17 kao inhibitori hiv-1

Country Status (38)

Country Link
US (4) US10421774B2 (hr)
EP (2) EP3831839B1 (hr)
JP (1) JP6735837B2 (hr)
KR (1) KR20180105229A (hr)
CN (1) CN109153700B (hr)
AR (1) AR107512A1 (hr)
AU (1) AU2017215529B2 (hr)
BR (1) BR112018015629B1 (hr)
CA (1) CA3013417C (hr)
CL (1) CL2018002084A1 (hr)
CO (1) CO2018008157A2 (hr)
CR (1) CR20180387A (hr)
CY (1) CY1124353T1 (hr)
DK (1) DK3411381T3 (hr)
DO (1) DOP2018000174A (hr)
EA (1) EA036211B1 (hr)
ES (2) ES2862325T3 (hr)
HK (1) HK1256866A1 (hr)
HR (1) HRP20210502T1 (hr)
HU (1) HUE054337T2 (hr)
IL (1) IL260741B (hr)
JO (1) JOP20170029B1 (hr)
LT (1) LT3411381T (hr)
MA (2) MA53358A (hr)
MD (1) MD3411381T2 (hr)
MX (1) MX2018009514A (hr)
PE (1) PE20181355A1 (hr)
PL (1) PL3411381T3 (hr)
PT (1) PT3411381T (hr)
RS (1) RS61746B1 (hr)
RU (1) RU2716502C2 (hr)
SG (1) SG11201806388XA (hr)
SI (1) SI3411381T1 (hr)
TW (1) TWI719126B (hr)
UA (1) UA123867C2 (hr)
UY (1) UY37109A (hr)
WO (1) WO2017134596A1 (hr)
ZA (1) ZA201805044B (hr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR107512A1 (es) * 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
EP4321164A3 (en) 2018-04-24 2024-04-17 ViiV Healthcare UK (No.5) Limited Compounds with hiv maturation inhibitory activity
TW202135815A (zh) 2019-12-09 2021-10-01 美商 Ｖｉｉｖ 醫療保健公司 醫藥組合物
WO2024089216A1 (en) 2022-10-27 2024-05-02 Syngenta Crop Protection Ag Novel sulfur-containing heteroaryl carboxamide compounds

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5679828A (en) 1995-06-05 1997-10-21 Biotech Research Labs, Inc. Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7365221B2 (en) 2002-09-26 2008-04-29 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
GB0301227D0 (en) 2003-01-20 2003-02-19 Keen Group Ltd Seating apparatus
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US20050239748A1 (en) 2004-03-17 2005-10-27 Panacos Pharmaceuticals, Inc. Pharmaceutical salts of 3-O-(3',3'-dimethylsuccinyl) betulinic acid
TW200628161A (en) 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
WO2008115281A2 (en) 2006-10-16 2008-09-25 Myriad Genetics, Inc. Compounds for treating viral infections
JP2011511812A (ja) 2008-02-14 2011-04-14 バイロケム ファーマ インコーポレイテッド 新規１７βルパン誘導体
US9067966B2 (en) 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
FR2956034B1 (fr) 2010-02-09 2012-02-10 Thales Sa Dispositif d'entrainement pour des joueurs de rugby
CA2801487C (en) 2010-06-04 2017-12-05 Bristol-Myers Squibb Company Modified c-3 betulinic acid derivatives as hiv maturation inhibitors
US8802661B2 (en) 2010-06-04 2014-08-12 Bristol-Myers Squibb Company C-28 amides of modified C-3 betulinic acid derivatives as HIV maturation inhibitors
DE102010017786A1 (de) 2010-07-07 2012-01-12 Continental Reifen Deutschland Gmbh Elastomerprodukt, enthaltend ein linienförmiges, textiles Gebilde zur Verstärkung
RS54352B1 (en) 2011-01-31 2016-02-29 Bristol-Myers Squibb Company C-28 AMINES OF C-3 MODIFIED BETULINIC ACID DERIVATIVES AS HIV INVESTIGATION INHIBITORS
CA2826113C (en) * 2011-01-31 2018-09-04 Bristol-Myers Squibb Company C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity
AU2012352129B2 (en) * 2011-12-14 2016-02-04 Glaxosmithkline Llc Propenoate derivatives of betulin
US8906889B2 (en) 2012-02-15 2014-12-09 Bristol-Myers Squibb Company C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity
US8889854B2 (en) 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
EP2935240A1 (en) 2012-12-21 2015-10-28 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US9378035B2 (en) 2012-12-28 2016-06-28 Commvault Systems, Inc. Systems and methods for repurposing virtual machines
EP2953960A1 (en) * 2013-02-06 2015-12-16 Bristol-Myers Squibb Company C-19 modified triterpenoids with hiv maturation inhibitory activity
CN105102468A (zh) 2013-02-25 2015-11-25 百时美施贵宝公司 用于治疗hiv的c-3烷基和烯基修饰的桦木酸衍生物
CN104877015B (zh) * 2014-02-28 2019-02-01 中国人民解放军军事医学科学院毒物药物研究所 一种三萜-多肽缀合物、其药物组合物及用途
CA2944778C (en) 2014-04-11 2022-06-14 ViiV Healthcare UK (No.4) Limited Triterpenoids with hiv maturation inhibitory activity
MA40886B1 (fr) 2015-02-09 2020-03-31 Hetero Research Foundation Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih
AR107512A1 (es) * 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
ES2907373T3 (es) 2016-02-04 2022-04-25 Takeda Pharmaceuticals Co Compuesto de piperidina sustituida y uso de la misma

Also Published As

Publication number Publication date
TW201739757A (zh) 2017-11-16
UY37109A (es) 2017-09-29
WO2017134596A1 (en) 2017-08-10
EP3411381B1 (en) 2021-01-20
EA201891649A1 (ru) 2019-02-28
EP3831839A2 (en) 2021-06-09
US20210323997A1 (en) 2021-10-21
RU2716502C2 (ru) 2020-03-12
EA036211B1 (ru) 2020-10-14
CY1124353T1 (el) 2022-07-22
RU2018130181A (ru) 2020-03-05
AU2017215529A8 (en) 2018-08-30
CA3013417C (en) 2024-01-02
CR20180387A (es) 2018-09-20
BR112018015629B1 (pt) 2023-10-24
SG11201806388XA (en) 2018-08-30
CN109153700B (zh) 2021-03-09
US20190359647A1 (en) 2019-11-28
IL260741B (en) 2020-04-30
CL2018002084A1 (es) 2018-09-21
EP3831839A3 (en) 2021-07-21
MA43960B1 (fr) 2021-02-26
TWI719126B (zh) 2021-02-21
AU2017215529A1 (en) 2018-08-23
AR107512A1 (es) 2018-05-09
CO2018008157A2 (es) 2018-08-21
MA43960A (fr) 2018-12-12
PE20181355A1 (es) 2018-08-22
US20190031709A1 (en) 2019-01-31
PT3411381T (pt) 2021-03-18
MA53358A (fr) 2021-07-21
US10421774B2 (en) 2019-09-24
MX2018009514A (es) 2018-09-05
ES2862325T3 (es) 2021-10-07
AU2017215529B2 (en) 2019-01-31
JOP20170029B1 (ar) 2021-08-17
RS61746B1 (sr) 2021-05-31
BR112018015629A2 (pt) 2018-12-26
HK1256866A1 (zh) 2019-10-04
ZA201805044B (en) 2020-08-26
US20230295220A1 (en) 2023-09-21
HUE054337T2 (hu) 2021-08-30
PL3411381T3 (pl) 2021-09-13
ES2957767T3 (es) 2024-01-25
JP2019504104A (ja) 2019-02-14
CA3013417A1 (en) 2017-08-10
LT3411381T (lt) 2021-04-26
US11084845B2 (en) 2021-08-10
EP3831839B1 (en) 2023-07-26
JP6735837B2 (ja) 2020-08-05
MD3411381T2 (ro) 2021-07-31
RU2018130181A3 (hr) 2020-03-05
DK3411381T3 (da) 2021-04-06
EP3411381A1 (en) 2018-12-12
SI3411381T1 (sl) 2021-04-30
KR20180105229A (ko) 2018-09-27
UA123867C2 (uk) 2021-06-16
DOP2018000174A (es) 2018-10-31
CN109153700A (zh) 2019-01-04

Similar Documents

Publication Publication Date Title
HRP20210502T1 (hr) Triterpenoidi modificirani na c-3 i c-17 kao inhibitori hiv-1
HRP20231018T1 (hr) Terapeutski spojevi korisni za profilaktičko ili terapijsko liječenje hiv virusne infekcije
HRP20180791T1 (hr) Glioksamid supstituirani derivati pirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b
HRP20200648T1 (hr) Derivati sulfamoilpirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b
HRP20161125T1 (hr) Makrociklički purini za liječenje virusnih infekcija
HRP20200379T1 (hr) Spojevi pirimidindiona protiv srčanih stanja
HRP20171512T1 (hr) Derivati betulina
HRP20181048T1 (hr) Neuroaktivni 19-alkoksi-17-supstituirani steroidi, korisni u postupcima liječenja
JP2013527242A5 (hr)
PE20212077A1 (es) Nuevos compuestos sulfonamida de carboxamida
RS54352B1 (en) C-28 AMINES OF C-3 MODIFIED BETULINIC ACID DERIVATIVES AS HIV INVESTIGATION INHIBITORS
HRP20230274T1 (hr) Kemijski spojevi
AR085203A1 (es) Inhibidores benzimidazol del virus sincitial respiratorio
WO2016009065A3 (en) Quinoline derivatives for the treatment of inflammatory diseases
WO2019035973A8 (en) Choline salt forms of an hiv capsid inhibitor
EA201890654A1 (ru) Терапевтические композиции для лечения вируса иммунодефицита человека
PE20142148A1 (es) Compuestos para el tratamiento y profilaxis de la enfermedad del virus sincicial respiratorio
EA201591457A8 (ru) Терапевтические соединения
HRP20220920T1 (hr) Pirolo[1,2-f][1,2,4]triazini koji su korisni za liječenje infekcija respiratornim sincicijalnim virusom
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
TR201909152T4 (tr) Polisiklik-karbamoilpiridon bileşikleri ve bunların farmasötik kullanımı.
JO3811B1 (ar) مركبات غير متجانسة حلقياً ثلاثية الحلقات ملتحمة تعمل في صورة مثبطات انزيم إنتيجراز hiv
PH12016502147A1 (en) Substituted 4-phenylpiperidines, their preparation and use
AR097082A1 (es) Compuestos terapéuticamente activos y sus métodos de uso
HRP20171102T1 (hr) Biaril- ili heterociklički biaril-supstituirani spojevi derivata cikloheksena kao inhibitori cetp